by our market research resources that there are approximately two
million bone grafting procedures in the United States every year. The
market for orthopedic biomaterials used in these procedures was
estimated to be approximately $4 billion in 2006. In addition, the
fastest growing segment of this market is recombinant protein products
which is expected to grow to $2.9 billion by 2012.
-- We are developing second-generation technetium-based imaging agents to
aid in the diagnosis of PD, Dementia with Lewy Bodies (DLB), and
Attention Deficit Hyperactivity Disorder (ADHD). We have previously
demonstrated in non-human primate studies that our technetium-based
agents are effective in binding the to DAT in sufficient quantity and
with high-selectivity to provide a readable image in the normal brain.
During 2007, we devised a new radiolabeling procedure for our
technetium agents that results in a high purity, high yield product as
a prelude to obtaining definitive images in non-human primates.
Continued Intellectual Property (IP) leadership notably in regenerative
Alseres' IP portfolio includes issued, allowed or granted patents from the
U.S. and other key countries worldwide. During 2007, the company
submitted 14 new patent applications covering our regenerative
therapeutics, molecular imaging, and neurodegenerative disease assets. We
were granted three new patents covering CETHRIN, four additional patents
covering other regenerative therapies and one patent covering our DAT
Business & Operational Highlights
Licensed Phase I/IIa Regenerative Therapeutics Program in acute SCI.
In December 2006, Alseres licensed, from BioAxone Therapeutic, Inc. of
Montreal, Canada, development and commercialization rights of CETHRIN, as<
|SOURCE Alseres Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved